Analysis of predictive value of animal repeated dose toxicity study results for clinical safety of US FDA-approved anticancer drugs between 2019 and 2023

Gyeyoung Choi, Seungjin Bae, Kyung-Min Lim

Open source

DOI
10.1016/j.yrtph.2026.106031
Published
2026-03
Container
Regulatory Toxicology and Pharmacology
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.yrtph.2026.106031,
  title = {Analysis of predictive value of animal repeated dose toxicity study results for clinical safety of US FDA-approved anticancer drugs between 2019 and 2023},
  author = {Gyeyoung Choi and Seungjin Bae and Kyung-Min Lim},
  year = {2026},
  journal = {Regulatory Toxicology and Pharmacology},
  doi = {10.1016/j.yrtph.2026.106031},
  url = {https://doi.org/10.1016/j.yrtph.2026.106031}
}

RIS

TY  - JOUR
TI  - Analysis of predictive value of animal repeated dose toxicity study results for clinical safety of US FDA-approved anticancer drugs between 2019 and 2023
AU  - Gyeyoung Choi
AU  - Seungjin Bae
AU  - Kyung-Min Lim
PY  - 2026
JO  - Regulatory Toxicology and Pharmacology
DO  - 10.1016/j.yrtph.2026.106031
UR  - https://doi.org/10.1016/j.yrtph.2026.106031
ER  - 

APA

Choi, G., Bae, S., & Lim, K. (2026). Analysis of predictive value of animal repeated dose toxicity study results for clinical safety of US FDA-approved anticancer drugs between 2019 and 2023. Regulatory Toxicology and Pharmacology. https://doi.org/10.1016/j.yrtph.2026.106031

Source records